- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Casodex ( Bicalutamide )
Casodex (bicalutamide) is a non‑steroidal antiandrogen indicated for the treatment of advanced prostate cancer in combination with a luteinizing hormone‑releasing hormone (LHRH) agonist (medical castration) or after surgical orchiectomy. Bicalutamide competitively binds to androgen receptors on prostate tumour cells, blocking the action of circulating testosterone and dihydrotestosterone. By inhibiting androgen‑mediated cell growth and differentiation, it slows disease progression. Casodex is not a chemotherapeutic agent and must be used together with continuous androgen deprivation therapy; it does not lower serum testosterone and should never be given as monotherapy for advanced disease except in selected patients under specialist supervision.
Usual adult dose: The recommended dose is one 50 mg tablet taken orally once daily, at approximately the same time each day. Treatment with Casodex is started concomitantly with an LHRH agonist (e.g., leuprolide, goserelin) or following bilateral orchiectomy. The tablet may be taken with or without food. No dose adjustment is required for elderly patients or those with mild renal impairment. In patients with moderate‑to‑severe hepatic impairment, bicalutamide is not recommended because of extensive hepatic metabolism and the risk of accumulation. If a dose is missed, it should be taken as soon as remembered, but two doses must not be taken on the same day. Treatment is continued as long as clinical benefit is maintained and unacceptable toxicity does not occur.
Dosage form: Film‑coated tablets: 50 mg (white to off‑white, round, biconvex, debossed with “50” on one side). Available in blister packs of 28 or 30 tablets.
Onset of action: Once steady‑state plasma levels are reached (approximately 4 weeks after starting once‑daily dosing), the antiandrogenic effect is fully established. Clinical benefit, reflected by a decline in prostate‑specific antigen (PSA) levels and delay in disease progression, is typically assessed after 3 to 6 months of combined therapy.
Duration of action: The elimination half‑life of the active (R)‑enantiomer of bicalutamide is approximately 6 days, which supports once‑daily dosing and maintains continuous androgen receptor blockade throughout the dosing interval. Upon discontinuation, the drug is slowly cleared over several weeks.
Alcohol recommendation: There is no known direct interaction between bicalutamide and alcohol. However, bicalutamide is extensively metabolized by the liver and can cause hepatotoxicity. Heavy alcohol consumption may further impair liver function and increase the risk of liver injury. Patients should limit alcohol intake and undergo regular liver function testing as recommended by their oncologist.
Most common side effects: Due to the associated LHRH agonist or surgical castration, the most frequent adverse effects are hot flashes, loss of libido, and impotence. Bicalutamide itself commonly causes breast tenderness and gynecomastia (breast enlargement), which may be severe; prophylactic breast irradiation or tamoxifen may be considered. Gastrointestinal effects include nausea, diarrhea, and abdominal pain. Hepatotoxicity, ranging from reversible transaminase elevations to severe hepatitis and rare cases of fatal hepatic failure, is a serious risk; liver function must be monitored at baseline, regularly during the first few months of therapy, and whenever symptoms suggestive of hepatitis develop. If jaundice or marked transaminase elevations occur, the drug should be interrupted or discontinued. Bicalutamide is a CYP3A4 substrate and may interact with strong CYP3A4 inhibitors. As a component of androgen deprivation therapy, bicalutamide may contribute to metabolic changes, osteoporosis, and cardiovascular risk. Women of child‑bearing potential must not handle broken tablets or use bicalutamide; if a female partner is or could become pregnant, barrier contraception is essential. Casodex must be prescribed and supervised by a healthcare professional experienced in oncology.
Would you like to try Casodex (Bicalutamide) without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
